ãã¡ãã¯äŒå¡éå®ãšãªã£ãŠãããŸãã
ãã°ã€ã³ããŠçãµã€ã®å
šãŠã®æ©èœã䜿ã
â SNSã§ãã°ã€ã³
äžèšSNSã¢ã«ãŠã³ãããæã¡ã®æ¹ã¯ãã¡ãŒã«ã¢ãã¬ã¹ã®å
¥åäžèŠã§ç°¡åç»é²
â ã¡ãŒã«ã¢ãã¬ã¹ã§ãã°ã€ã³
ã¢ã«ãŠã³ãããæã¡ã§ãªãæ¹ã¯ãã¡ã
ã€ã³ãã®ããªãŒã§ã¯
WHOçã«å察ãããªãã
ã€ãã«ã¡ã¯ãã³ã倧éã«æäžã
äžæ¥ã®ææè
æ°ã
2äž8å人ïŒ4/20æ¥ïŒ
â¡2çŸäººå°ïŒ6/12æ¥ïŒã«è¿
倧å¹
ã«æžå°ãããã
ïŒbyãæ¥æ¬è²¿ææ¯èæ©æ§ïŒ
- [å¿åãã]
ã€ãã«ã¡ã¯ãã³æãŠã£ãŠæµãã«ãªããªãã®ã¯ããã¬ããã¯ã¯ãã³æãããŠå²ããããæ¥æ¬ã®çµæžå£ããããšããç Žå£å·¥äœå¡ã°ããã ãã
- [å¿åãã]
>>20
ç¥ãã³ãã£ããã
ãªããæ¥æ¬ã¯ãæ¿èªããªã£ãïŒ
- [å¿åãã]
WHOã¯æåããæ²»çè¬ãããã®ã
èªèããŠãããã¯ã¯ãã³èšç»ã®çº
æå¹æ§ã¯ç¡ããšãããã ãããª
- [å¿åãã]
#10â2021/07/31 22:49
>>8
ãããã§ãäœããã¯ãã ãã補è¬äŒç€Ÿãå²ãããªãã®ã§äœããªããããããšã®ã¡ã«ã¯ã¯æ°è¬ãæåãããããã«ãã€ãã«ã¡ã¯ãã³çç£æå¶ããŠãã
[å¿åãã]
- [å¿åãã]
#8â2021/07/31 20:09
>>7
ã€ãã«ã¡ã¯ãã³ãªããŠãšã£ãã®æã«ç¹èš±ãåããŠããŠåŸçºåããããã§ãé ãããã§ããã©ïœ
[å¿åãã]
#9â2021/07/31 20:15
>>7
ã€ã³ãã§ã¯åœå¶è£œè¬ã¡ãŒã«ãŒã«å€§éã«çç£ãããŠã¯ããŸããå¹æãªãããã§ãã
[å¿åãã]
- [å¿åãã]
ERã®å»è
ããã飲ãã§äŒã¿ã®æ¥ã«éã³ã«è¡ããšã
- [å¿åãã]
ã€ãã«ã¡ã¯ãã³ã䜿çšããŠããããã®ãã¡15ãåœãå
¬åŒã«æ¿èªãããŠããŸãã ãè±åœã®ã€ãã«ã¡ã¯ãã³æšå¥šéçºïŒBIRDïŒããã«-2021幎3æ25æ¥
ãäžç床/é床ã®ææçã«é¢ãã11件ã®ã©ã³ãã åè©Šéšã§ãæ»äº¡çã56ïŒ
æžå°ããŸããã
ã軜床/äžç床ã®åå è
ã®ãµãã°ã«ãŒãã§ã¯çåçã70ïŒ
æ¹åããŸããã
SARS-CoV-2ææçãæ²»çããããã®ã€ãã«ã¡ã¯ãã³ã®ã©ã³ãã åè©Šéšã®ã¡ã¿ã¢ããªã·ã¹-2021幎7æ
è±åœãªãããŒã«å€§åŠã®ã¢ã³ããªã¥ãŒãã«å士ïŒçé èè
ããã³WHOé¢é£ç 究è
ïŒ
- [å¿åãã]
exstnc.com
ãããããã«ã³ã¯ãã³
- [å¿åãã]
æ¥æ¬ã§ãæ©ãã€ãã«ã¡ã¯ãã³äœ¿ãã
- [å¿åãã]
>>7
ããäžæ¢ãããããã§ã
ãã£ãœã©ã¯ã¯ãã³ã«äžéœåãªãã ããã
- [å¿åãã]
>>0
ã€ã³ãã®æææ»ãæ¿åºçºè¡šã®ïŒïŒåãâŠç«è¬æ°ã¯ãã¡ãã£ã¢ã«æãããªã
2021/07/23 12:42ããããããããããèªå£²æ°èãªã³ã©ã€ã³
ãç±³åœã®ç 究æ©é¢ãäžçéçºã»ã³ã¿ãŒãã¯ïŒïŒæ¥ãã€ã³ãã®ä»å¹ŽïŒæãŸã§ã®æ°åã³ãããŠã€ã«ã¹ã«ããæ»è
æ°ããïŒïŒïŒäžäººååŸã«åã¶ãšã®æšèšãçºè¡šãããã€ã³ãæ¿åºã®çºè¡šã¯çŽïŒïŒäžäººã§ããã®ïŒïŒåã®èŠæš¡ã«ãªãã
ã幎霢局å¥ã®èŽæ»çãæææŽãªã©ãç·åããŠæšèšããããã€ã³ãæ¿åºã¯ãã®çºè¡šã«å¯Ÿãããæ»è
æ°ãé ãçç±ã¯ãªãããªã©ãšåè«ããã
ãã€ã³ãã§ã¯ãå®éã®æ»è
æ°ã¯å
¬åŒçµ±èšãããå€ããšã®ææãã¡ãã£ã¢ãªã©ã§çžæ¬¡ããéŠéœè¿éã®ç«è¬å Žé¢ä¿è
ã¯ãæ¬çŽã«ãæšå¹Žã®ããæã¯ïŒïŒïŒäœç«è¬ããããå°å
æ¿åºã®çºè¡šã¯ïŒïŒäœçšåºŠã ã£ããææ°ã®æ°åã¯ãã¡ãã£ã¢ã«æããªãããã«ããšæ瀺ãããããšèªã£ãã
- [å¿åãã]
- ãã®æçš¿ã¯åé€ãããŸãã
>>27
æ¥æ¬ãå
¬èªããŠã»ããããª
- [å¿åãã]
(ãã»Ïã»)ããªãªãªã©ã©ã©-
- [å¿åãã]
æ¥æ¬ã¯èªããªããã¢ã¡ãªã«ãã€ã³ããWHOãèªããŠã!
åçåŽåçã¯æ²»éšãæ²»éšã人åœããæ²»éšã
ä»åœã§å¹æããã®ã«ãå€ãªåœ!
- [å¿åãã]
>>35
ã補è¬ã¡ãŒã«ãŒã®æ¥çå£äœã§ãããæ¥æ¬è£œè¬å·¥æ¥åäŒãã¯çäºé·ãšããŠå
åçåŽåçå®åã®çœç³é äžæ°ãåãå
¥ããŠããŸãã
ãŸã倧éªå»è¬ååäŒã§ãå
åçåŽåçå®åã®ä»å¥åºæéæ°ãåãå
¥ããŠããŸããããããæ°åäžåã®å ±é
¬ãæãããŠãããã®ãšã¿ãããŠããŸãã
ttps://www.mag2.com/p/news/488437/amp#clickâ=hâttps://t.co/TfOVwzQMju
- [å¿åãã]
>>35
æ¬åœã«éã®æ¿åºã«æ¯é
ãããŠããŸã£ãŠãããããªãããã®åœã¯ã
è
ãããã¯ããç·ç倧è£ãªããŠãã ã®é£Ÿãã
- [å¿åãã]
(ãã»Ïãã¶ïœã»)ãïœïœïœãªãªïŒïŒïŒãªã©ã©ã©-
- [å¿åãã]
è¬åŠéšã®äººããå±ãªãå¯äœçšããè¬ã«ãŠãããªããŠãäººæ Œé害ã®
人ãè¬åŠéšã«æ··ãã£ãŠããŠæããŠèšã£ãŠãŸããã
ããšåè¬å©çãè·³ãäžããããã®ãããŒå©çã
ã®ã£ã³ãã«çããŒããã©ãã°ç¶æ
ãšãªã£ãŠããè
ã
èªç€Ÿãåè¬å©çã®åŠšããšãªããªãã培åºç朰ããš
ååŽçè·å¡ã«.. é¢è¥¿åŒã ã£ããšã®äºã§ãã
- [å¿åãã]
>>39ç¶
誰ã®ãããã§åºäžãåºæ¥ããšæã£ãŠãããšååŽçè·å¡ãè
ãã
代æ¿è¬èªå¯ã劚害ããããã§ãã
- [å¿åãã]
å»è
ãšè£œè¬äŒç€Ÿã¯æããã®èŠªåé¢ä¿å€ãããã®ç¶æãã
å€æããŠããšã
- [å¿åãã]
å¹æããããšã¯èšããªããšçµè«ãåºãŠããã«
- [å¿åãã]
ã€ã³ãã®ããªãŒã¯4äžæ¬ããã³ãã察çã§
ããã¯ããŠã³ãå€åºçŠæ¢ãªã©ãããçµæ
ã³ããææè
æžã£ãã®ã§ãã£ãŠ
ã€ãã«ã¡ã¯ãã³ã®å¹æã®ããããã§ã¯ãªãã
ããããå³ããå¶éããããŠæžãããŠãã®ã«
ã€ãã«ã¡ã¯ãã³æšé²æã¯æžã£ãã®ã¯ã€ãã«ã¡ã¯ãã³
ã®ãé°ã ãšéšãã§ãã
èŠã¯ãã ã®æ°Žéæ°Žãç¥ã®è¬ãšããã®èŸºã®ç³ã綺éºã«ç£šããŠãã®ç³ã«ã¯ç¥ã®åããšãèšã£ãŠå£²ãæ©ãå€ãªå®æå£äœãšäžç·ã
çãããéšãããªãããã«ïŒ
æ¥æ¬ã§èšããšã³ããã®æ²»çãšããŠã¢ãã¬ã³ãªã©ã®æãŠã€ã«ã¹è¬ã䜿ã£ãŠæ²»çããŠäœäžäººãæ²»ã£ãŠãŸãããïŒ
- [å¿åãã]
ã§ããªãã§ã€ãã«ã¡ã¯ãã³ã®ãããã§æžã£ããšãã説ãä¿¡ã蟌ãã 人ãå¢ãããã ããã
åã«ã»ãå¹æããã£ãã ããšéœåãã解éããã ããªã®ãã
- [å¿åãã]
>>43
å¥ã«ã€ãã«ã¡ã¯ãã³æšé²æŽŸã§ããªããããã®æèŠïŒã«ãè³åããããã
åŠã«åŠå®ããã®ãäžèªç¶ã§ãè©ŠããŠã¿ãŠãè¯ããããªæ°ããããããã§ãã¡ãªã次èããã°è¯ãã
- [å¿åãã]
>>45
ã§ããŸãææè
æ°æžå°ã®çç±ãå
šãŠã€ãã«ã¡ã¯ãã³ã®å¹æã ãšå°è±¡ä»ãããããªè¡šçŸã¯é倧è©äŸ¡ã«ã€ãªããããª
- [å¿åãã]
æåŸ
ãããŠã¯ãããªãããã¯ã¯ãã³ãšéã£ãŠãªã¹ã¯ãäœããã ããåœæ°ã«è©Šãããæ©äŒãäžããŠæ¬²ããïŒ
- [å¿åãã]
>>47
æ°åã³ãããŠã€ã«ã¹ææçïŒCOVID-19ïŒ èšºçã®æåŒã ãèªãã§ããã
- [å¿åãã]
ã©ãã®éšåãèªãã ãè¯ããã§ããïŒ
- [å¿åãã]
å»åž«äž»å°åã®æ²»éšã¯ç¶ç¶äžãã£ãœãããšãæåŒãã«ã¯æžããŠãããŸãããããããå»åž«ãç©æ¥µçã«äœ¿ãã®ã¯èºèºããŸãããïŒ
- [å¿åãã]
æ²»çè¬ãšããŠæ¿èªãããŠããªããæ²»éšäž
æåŒãã«èšèŒãããŠããID jRCT2031200120 ã§æ€çŽ¢ãããšæ²»éšã®å®æœèšç»ãé²èŠ§ã§ãã
æ
å ±ã¯ãªãŒãã³ã«ãããŠããã£ãŠããšã ãª
- [å¿åãã]
ããããšãããããŸããèŠãŠã¿ãŸãã
- [å¿åãã]
ãæ²å ±ãéççéæåŸ
ã®æ°åã³ããæ²»çè¬ãã€ãã«ã¡ã¯ãã³ã倧èŠæš¡ç 究ãå¹æãªãã
ç·šéæ¥ 2021幎8æ14æ¥ãæ±äº¬ã»ããã«ãã¯ãªãã㯠> 仲ç°æŽçŸãªãã£ã·ã£ã«ããã°
ttps://minerva-clinic.or.jp/blog/ivermectin-study-no-effect/
ããæç²
æè¿æ¥æ¬ã§ããé·å°Ÿåå®ãããæ±äº¬éœå»åž«äŒé·ã®å°ŸåŽæ²»å€«ãããåææŽå€«åŒè·å£«ãåæä»å»åž«ãçå±±ãã€ãè¡è°é¢è°å¡ãªã©ãã€ãã«ã¡ã¯ãã³ã«é¢ããŠãããé£ã°ããç©è°ãããããŠãããŸãããããããéççéã«å
¥ããã»ããããã®ãããããŸããã
ã€ãã«ã¡ã¯ãã³ã¯ä»ãã1é±éã»ã©åã®8æ6æ¥ãç±³åœåœç«è¡çç 究æïŒNIHïŒäž»å¬ã®ã·ã³ããžãŠã ã§ã©ã³ãã åæ¯èŒè©ŠéšïŒRCTïŒã§ãã®å¹æãåŠå®ãããããšããã§ã«å ±åãããŠããŸãã
ã€ãã«ã¡ã¯ãã³ã¯COVID-19ã®ææ°ã®æ²»çæ³ãšãããåã¯ã¯ãã³æ¥çš®ã°ã«ãŒãã«ãã£ãŠå®£äŒãããŠãããããªã®ã§ããã倧èŠæš¡ãªæ£è
調æ»ã«ãããšãCOVID-19ã«ã¯ãå
šãå¹æããªãããšãšå ±åã8æ6æ¥ã«ãªãããŸããã
- [å¿åãã]
ãããç±³åœã¯ã€ãã«ã¡ã¯ãã³åŠå®ãããããå®éšãã©ããŸã§ä¿¡ããŠè¯ããã
å¹ããªãè¬ãã¡ãŸãã«ã¯ãã£ã±ãåºãŸãã£ãŠãããšã ããã€ãã«ã¡ã¯ãã³ãããã£ãšæ®éã«åºãŸãããªãããªã
ã€ãã«ã¡ã¯ãã³è«äºãäœæ
ã«ç®ãããç«ãŠã人å€ããã ããïŒ
- [å¿åãã]
- ãã®æçš¿ã¯åé€ãããŸãã
Ivermectin for COVID-19: real-time meta analysis of 63 studies
- [å¿åãã]
ã€ãã«ã¡ã¯ãã³ã®æå¹æ§ãèªããããšã¯ãã¯ã¯ãã³æ¿çãå±éºã«ãããå¯èœæ§ããããããã¢ã¡ãªã«åœç«è¡çç 究æ ã CDC ã FDA ãèš±å¯ã§ããªã
- [å¿åãã]
ç±³åœã¯æãã©ãªã¢è¬ã»ããããã·ã¯ãããã³ã®æ²»çè¬ãšããŠã®ç·æ¥äœ¿çšèš±å¯ãåŸã«æ€åãšããçµéšãããããæ
éã«ãªããããåŸãªãããª
- [å¿åãã]
>>57
ããã€ã¯æšé²æŽŸã®ãµããããè£åãè
ã®ãŠãã§ãïŒ
ã€ãã«ã¡ã¯ãã³ããããšç¥ã®è¬ãšèšããµãããŠ
ã€ãã«ã¡ã¯ãã³ãè¡æ£èãè¬ãšæãããããŠãã§ãïŒ
ããã€ã®èšãäºãå¹ããªãã§äžããïŒ
- [å¿åãã]
,,,,;;;;;;................................
- [å¿åãã]
âð³âŠ
- [å¿åãã]
>>57
ã€ãŸãã人ã®åœãããã¯ã¯ãã³ã§å²ãããŒãã«ãã®æ¹ã倧äºã£ãŠããšãã
- [å¿åãã]
>>57
FDAã¯æ¿åºè³æ¬100%ãã補è¬ã60%ä»ã¯éã ããŠãŸããã€ãŸããã€ãã«ã¡ã¯ãã³æ¢ããŠæ®ºäººã¯ã¯ãã³ãšããã£ãŠãŠãèš±å¯ããŸããã ããã€ããè¬ãã£ãŠãŠèš±å¯ããŠããŸãã
- [å¿åãã]
- ãã®æçš¿ã¯åé€ãããŸãã
- ãã®æçš¿ã¯åé€ãããŸãã
äžçªãããããã
- [å¿åãã]
..............;;;;;;;;;;;;;;;;,,,,,,,,,,,,,,,,,,,,,,,,,,,,
- [å¿åãã]
æ±äº¬ãïŒïŒæ¥ããã€ã¿ãŒïŒœ - èåïŒåå€å±åžïŒã¯ïŒïŒæ¥ãæ°åã³ãããŠã€ã«ã¹ææçã®æ²»çè¬ãšããŠç¬¬ïŒçžèšåºè©Šéšãè¡ã£ãŠãããã€ãã«ã¡ã¯ãã³ãã«ã€ããŠãåé倧åŠãšã®å
±åç 究ïŒéèšåºè©ŠéšïŒããããªãã¯ãã³æ ªã«å¯ŸããŠãããã«ã¿æ ªãªã©ã®æ¢åã®å€ç°æ ªãšåçã®æãŠã€ã«ã¹å¹æãããããšã確èªãããšçºè¡šããã
ãã€ãã«ã¡ã¯ãã³ãã¯ãïŒïŒïŒïŒå¹Žã«ããŒãã«ççåŠã»å»åŠè³ãåè³ããåé倧åŠã®å€§ææºç¹å¥æ èªææã®ç 究ãåºã«éçºããã飲ã¿è¬ãå¯çè«ææçæ²»çè¬ãšããŠãã¢ããªã«è«žåœãäžå¿ã«äœ¿ãããŠãããçŸåšãæ°åã³ããæ²»çè¬ãšããŠèšåºè©Šéšãè¡ã£ãŠããã
- [å¿åãã]
1æ1æ¥ä»¥éãäžå¹Žå±€ãè¥å¹Žå±€ã®ã³ããæ»è
ïŒïŒïŒæ³ä»¥äžïŒãïŒïŒä»£ïœïŒïŒä»£
ãâ»ãã ããäžéšã®èªæ²»äœã§è©³çŽ°éå
¬è¡šãéºæã®æåã§éå
¬è¡šãããããã詳现ãå€æããŠããæ»äº¡è
ã®ã¿ã§ã
âã¯ã¯ãã³æ¥çš®æžãã1人
ãã»50代ã1人
âã¯ã¯ãã³æªæ¥çš®ã42人
ãã»10代ãã1人
ãã»20代ãã2人
ãã»30代ãã7人
ãã»40代ã10人
ãã»50代ã22人
1æ23æ¥ã«è¡ãããåã¯ã¯ãã³ã»åãã¹ã¯ãã¢ã«åå ããïŒïŒä»£ç·æ§ãã³ããã§æ»äº¡
ã€ãã«ã¡ã¯ãã³æšé²æŽŸã§ããã£ãäºããã€ãã«ã¡ã¯ãã³æçšããŠãããšæããã
ããã®éŠ¬é¹¿ã蚌æããäºã
ã»ãã¹ã¯ãããªããã°ã³ããã«ææãããâãã¹ã¯ã¯ææäºé²å¹ææã
ã»ã¯ã¯ãã³æããªããã°ïŒïŒä»£ã§ãã³ããã§æ»ã¬ãâã¯ã¯ãã³ã¯éçãæ»äº¡äºé²å¹ææã
ã»ã€ãã«ã¡ã¯ãã³ãæçšããŠãã³ããã§æ»ã¬âã€ãã«ã¡ã¯ãã³å¹æç¡ã
åã¯ã¯ãã³çéã¯ãããã©ãããã®ïŒwwwww
åã¯ã¯å€§çºçãåãã¹ã¯å€§çºçãã€ãã«ã¡ã¯ãã³æšé²æŽŸå€§çºçwwwwww
以äžãIQãäœã瀟äŒäžé©åã銬鹿ã®ã¿ãªãããâçµæãå
šãŠâãå°ãã¯åŠç¿ããŸããããwwwwwww倧çç¬wwwwwww
- [å¿åãã]
............;;;;;;;;;;;;;;;;,,,,,,,,,,,,,,,,,,,,,,,,,,,,
- [å¿åãã]
|
|